{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:02:07Z","timestamp":1771545727214,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-37412-2","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T07:14:16Z","timestamp":1770016456000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Oxford versus Japanese Histological Grading to predict renal function decline in IgA nephropathy: a Japanese prospective cohort study"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8844-9811","authenticated-orcid":false,"given":"Ryoko","family":"Sakaguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9334-3664","authenticated-orcid":false,"given":"Kensuke","family":"Joh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7402-5125","authenticated-orcid":false,"given":"Shiko","family":"Honma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6455-071X","authenticated-orcid":false,"given":"Akinori","family":"Hashiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0360-1568","authenticated-orcid":false,"given":"Ritsuko","family":"Katafuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6649-9535","authenticated-orcid":false,"given":"Masako","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2313-8937","authenticated-orcid":false,"given":"Keita","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5407-5265","authenticated-orcid":false,"given":"Nobuo","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8376-5273","authenticated-orcid":false,"given":"Tetsuya","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1838-7998","authenticated-orcid":false,"given":"Takashi","family":"Yokoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4077-9747","authenticated-orcid":false,"given":"Yusuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"37412_CR1","doi-asserted-by":"publisher","first-page":"1436923","DOI":"10.3389\/fimmu.2024.1436923","volume":"15","author":"EJ Filippone","year":"2024","unstructured":"Filippone, E. J., Gulati, R. & Farber, J. L. Contemporary review of IgA nephropathy. Front. Immunol. 15, 1436923 (2024).","journal-title":"Front. Immunol."},{"key":"37412_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091756","volume":"9","author":"T Moriyama","year":"2014","unstructured":"Moriyama, T. et al. Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan. PLoS ONE 9, e91756 (2014).","journal-title":"PLoS ONE"},{"key":"37412_CR3","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","volume":"91","author":"H Trimarchi","year":"2017","unstructured":"Trimarchi, H., Barratt, J. & Cattran, D. C. Oxford classification of IgA nephropathy 2016: An update from the IgA Nephropathy Classification Working Group. Kidney Int 91, 1014\u20131021 (2017).","journal-title":"Kidney Int"},{"key":"37412_CR4","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/ki.2009.243","volume":"76","author":"DC Cattran","year":"2009","unstructured":"Cattran, D. C., Coppo, R. & Cook, H. T. The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int 76, 534\u2013545 (2009).","journal-title":"Kidney Int"},{"key":"37412_CR5","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.34067\/KID.0000000000000195","volume":"4","author":"AJ Howie","year":"2023","unstructured":"Howie, A. J. & Lalayiannis, A. D. Systematic review of the oxford classification of IgA nephropathy: Reproducibility and prognostic value. Kidney 360 4, 1103\u20131111 (2023).","journal-title":"Kidney 360"},{"key":"37412_CR6","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1007\/s10157-017-1393-x","volume":"21","author":"AB Kaihan","year":"2017","unstructured":"Kaihan, A. B. et al. The japanese histologic classification and T-score in the Oxford Classification system could predict renal outcome in Japanese IgA nephropathy patients. Clin. Exp. Nephrol. 21, 986\u2013994 (2017).","journal-title":"Clin. Exp. Nephrol."},{"key":"37412_CR7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1681\/ASN.2016040433","volume":"28","author":"M Haas","year":"2017","unstructured":"Haas, M. et al. A multicenter study of the predictive value of crescents in IgA nephropathy. J. Am. Soc. Nephrol. 28, 691\u2013701 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"37412_CR8","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","volume":"179","author":"SJ Barbour","year":"2019","unstructured":"Barbour, S. J. et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA. Intern. Med. 179, 942 (2019).","journal-title":"JAMA. Intern. Med."},{"key":"37412_CR9","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1007\/s40620-024-01985-w","volume":"37","author":"RS Lim","year":"2024","unstructured":"Lim, R. S. & Yeo, S. C. External validation of international IgA nephropathy prediction tool in a Singapore Cohort (EXIST Study). J. Nephrol. 37, 2409\u20132412 (2024).","journal-title":"J. Nephrol."},{"key":"37412_CR10","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/nep.13865","volume":"26","author":"D Hwang","year":"2021","unstructured":"Hwang, D. et al. Validation of an international prediction model including the Oxford classification in Korean patients with IgA nephropathy. Nephrology 26, 594\u2013602 (2021).","journal-title":"Nephrology"},{"key":"37412_CR11","doi-asserted-by":"publisher","first-page":"350","DOI":"10.5301\/jn.5000151","volume":"26","author":"T Kawamura","year":"2013","unstructured":"Kawamura, T. et al. A histologic classification of IgA nephropathy for predicting long-term prognosis: Emphasis on end-stage renal disease. J. Nephrol. 26, 350\u2013357 (2013).","journal-title":"J. Nephrol."},{"key":"37412_CR12","doi-asserted-by":"crossref","unstructured":"Joh, K. & McNamara, K. M. Differences of histological classification between the Japanese Histological Grade Classification and the Oxford Classification. In Pathogenesis and Treatment in IgA Nephropathy 69\u201387. Springer Japan (2016).","DOI":"10.1007\/978-4-431-55588-9_5"},{"key":"37412_CR13","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/ckj\/sfad294","volume":"17","author":"K Koike","year":"2024","unstructured":"Koike, K. et al. Clinicopathological prognostic stratification for proteinuria and kidney survival in IgA nephropathy: A Japanese prospective cohort study. Clin. Kidney. J. 17, 294 (2024).","journal-title":"Clin. Kidney. J."},{"key":"37412_CR14","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10157-014-1004-z","volume":"19","author":"R Sato","year":"2015","unstructured":"Sato, R. et al. Validation of the Japanese histologic classification 2013 of immunoglobulin A nephropathy for prediction of long-term prognosis in a Japanese single-center cohort. Clin. Exp. Nephrol. 19, 411\u2013418 (2015).","journal-title":"Clin. Exp. Nephrol."},{"key":"37412_CR15","doi-asserted-by":"publisher","first-page":"7339","DOI":"10.3390\/jcm12237339","volume":"12","author":"C-H Chen","year":"2023","unstructured":"Chen, C.-H., Wu, M.-J. & Tsai, S.-F. The Feasibility of Japanese Histological Grade Classification for predicting renal function deterioration among Taiwanese individuals with IgA nephropathy. J. Clin. Med. 12, 7339 (2023).","journal-title":"J. Clin. Med."},{"key":"37412_CR16","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/ki.2009.168","volume":"76","author":"IS Roberts","year":"2009","unstructured":"Roberts, I. S., Cook, H. T. & Troyanov, S. The Oxford classification of IgA nephropathy: Pathology definitions, correlations, and reproducibility. Kidney Int. 76, 546\u2013556 (2009).","journal-title":"Kidney Int."},{"key":"37412_CR17","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/ki.2014.63","volume":"86","author":"R Coppo","year":"2014","unstructured":"Coppo, R. et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 86, 828\u2013836 (2014).","journal-title":"Kidney Int."},{"key":"37412_CR18","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s10157-013-0856-y","volume":"18","author":"O Uemura","year":"2014","unstructured":"Uemura, O. et al. Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease. Clin. Exp. Nephrol. 18, 626\u2013633 (2014).","journal-title":"Clin. Exp. Nephrol."},{"key":"37412_CR19","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo, S. et al. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis. 53, 982\u2013992 (2009).","journal-title":"Am. J. Kidney Dis."},{"key":"37412_CR20","unstructured":"Akaike, H. Information theory and the maximum likelihood principle in 2nd International Symposium on Information Theory (1973)."},{"key":"37412_CR21","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1214\/aos\/1176344136","volume":"6","author":"G Schwarz","year":"1978","unstructured":"Schwarz, G. Estimating the dimension of a model. Ann. Statist. 6, 461\u2013464 (1978).","journal-title":"Ann. Statist."},{"key":"37412_CR22","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1198\/016214507000000149","volume":"102","author":"H Uno","year":"2007","unstructured":"Uno, H., Cai, T., Tian, L. & Wei, L. J. Evaluating prediction rules fort-year survivors with censored regression models. J. Am. Stat. Assoc. 102, 527\u2013537 (2007).","journal-title":"J. Am. Stat. Assoc."},{"key":"37412_CR23","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens, P. E. et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney. Int. 105, S117\u2013S314 (2024).","journal-title":"Kidney. Int."},{"key":"37412_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/sim.4026","volume":"30","author":"LE Chambless","year":"2011","unstructured":"Chambless, L. E., Cummiskey, C. P. & Cui, G. Several methods to assess improvement in risk prediction models: Extension to survival analysis. Stat. Med. 30, 22\u201338 (2011).","journal-title":"Stat. Med."},{"key":"37412_CR25","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/aje\/kws207","volume":"176","author":"MJ Pencina","year":"2012","unstructured":"Pencina, M. J., D\u2019Agostino, R. B., Pencina, K. M., Janssens, A. C. J. W. & Greenland, P. Interpreting incremental value of markers added to risk prediction models. Am. J. Epidemiol. 176, 473\u2013481 (2012).","journal-title":"Am. J. Epidemiol."},{"key":"37412_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","volume":"367","author":"LA Linker","year":"2012","unstructured":"Linker, L. A. et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N. Engl. J. Med. 367, 20\u201329 (2012).","journal-title":"N. Engl. J. Med."},{"key":"37412_CR27","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/ki.2011.126","volume":"80","author":"AM Herzenberg","year":"2011","unstructured":"Herzenberg, A. M. et al. Validation of the Oxford classification of IgA nephropathy. Kidney. Int. 80, 310\u2013317 (2011).","journal-title":"Kidney. Int."},{"key":"37412_CR28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/ki.2015.322","volume":"89","author":"SJ Barbour","year":"2016","unstructured":"Barbour, S. J., Espino-Hernandez, G. & Reich, H. N. The MEST score provides earlier risk prediction in lgA nephropathy. Kidney Int. 89, 167\u2013175 (2016).","journal-title":"Kidney Int."},{"key":"37412_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0268731","volume":"17","author":"K Joh","year":"2022","unstructured":"Joh, K. et al. Structural modeling for Oxford histological classifications of immunoglobulin A nephropathy. PLoS ONE 17, e0268731 (2022).","journal-title":"PLoS ONE"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37412-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37412-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37412-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:04:35Z","timestamp":1771542275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37412-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["37412"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-37412-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y.S. has received consulting fees from Otsuka Pharmaceutical, Novartis, Chinook Therapeutics, Argenx, BioCryst, Alexion Pharmaceuticals, Renalys, Alpine, and George Clinical. Y.S. has also received compensation for academic or educational activities from Kyowa Kirin, Novartis, Mitsubishi Tanabe, Otsuka Pharmaceutical, DAIICHI SANKYO, AstraZeneca, Boehringer Ingelheim, and Chinook Therapeutics. The remaining authors have no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6995"}}